Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China
Technology in Cancer Research & Treatment · 2023
DOI: 10.1177/15330338221148802 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, 2023. Verfasst von Tao Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Medical Center of PLA General Hospital, Graduate School, Medical College of Chinese PLA, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In the era of precision medicine, with the deepening of the research on malignant tumor driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small-cell lung cancer (NSCLC), the development of targeted drugs targeting driver genes, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), has successfully opened up a new model of targeted therapy. At present, proto-oncogene rearranged during transfection (RET) fusion gene is an important novel oncogenic driving target, and specific receptor tyrosine kinase inhibitors (TKIs) targeting RET fusion have been approved. This article will review the latest research about the molecular characteristics, pathogenesis, detection, and clinical treatment strategies of RET rearrangements especially in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Medical Center of PLA General Hospital, Graduate School, Medical College of Chinese PLA, Beijing, China.
- Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs (Ministry of Education), China.
- School of Medicine, Nankai University, Tianjin, China.
- Department of Pulmonary and Critical Care Medicine, The Second Medical Center of PLA General Hospital, Beijing, China.
- Graduate School, Medical College of Chinese PLA, Beijing, China.
- Department of Nutriology, The First Medical Center of PLA General Hospital, Graduate School, Medical College of Chinese PLA, Beijing, China.
ORCID-Profile: Tao Li, Ting-Ting Liu, Yi Hu
Zitieren
APA
Li, T., Yang, W. Y., Liu, T. T., Li, Y., Liu, L., Zheng, X., Zhao, L., Zhang, F., & Hu, Y. (2023). Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338221148802
Vancouver
Li T, Yang WY, Liu TT, Li Y, Liu L, Zheng X, et al. Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China. Technology in Cancer Research & Treatment. 2023. doi:10.1177/15330338221148802
BibTeX
@article{Li2023,
author = {Li, Tao and Yang, Wen-Yu and Liu, Ting-Ting and Li, Yao and Liu, Lu and Zheng, Xuan and Zhao, Lei and Zhang, Fan and Hu, Yi},
title = {Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China},
journal = {Technology in Cancer Research & Treatment},
year = {2023},
doi = {10.1177/15330338221148802}
}
EUVIMED